Axonics Inc (NAS:AXNX)
$ 67.22 -0.11 (-0.16%) Market Cap: 3.43 Bil Enterprise Value: 3.13 Bil PE Ratio: 0 PB Ratio: 5.47 GF Score: 83/100

Axonics Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 12:30AM GMT
Release Date Price: $64.73 (+4.81%)
Andrew Lang

Good afternoon, and thank you for joining us this week at the JPMorgan Healthcare Conference. I'm Andrew Lang with JPMorgan. And with me today to present from the company is Raymond Cohen, CEO of Axonics. Dan Dearen, Chief Financial Officer, will also be joining for Q&A. Ray, I'll turn it over to you.

Raymond W. Cohen
Axonics, Inc. - CEO & Director

Thank you. So good evening. I'm cognizant of the fact that it's now 4:30, and the only thing standing between you and cocktail would be my presentation. So we'll try to be brief. So thanks for attending.

Axonics is clearly focused on being able to treat women primarily who have some form of incontinence, whether that's fecal incontinence, whether it's our urge urinary incontinence where people can't get to the bathroom in time or stress urinary incontinence, which affects a lot of women following childbirth, where the cost needs to pick up an object or exercise and leak a little bit of urine. So that's our business. That's what we're focused on.

We've been public since October

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot